UPDATE 1-Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer
May 15, 2020 at 15:54 PM EDT
Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug's use as monotherapy in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite chemotherapy and hormone-directed therapy, the company said.